Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
NAA20P1 is a pseudogene of the human NAA20 (N-alpha-acetyltransferase 20, NatB catalytic subunit) gene[2]. It does not encode a functional protein. Pseudogenes are non-functional DNA segments that resemble known genes but typically lack biological activity due to disabling mutations or loss of regulatory elements. While the functional NAA20 gene is a catalytic component of the NatB N-terminal acetyltransferase complex involved in N-terminal acetylation of proteins, NAA20P1 lacks evidence of being translated or functioning as a therapeutic target[2]. There is no current evidence linking NAA20P1 to disease mechanisms, drug interactions, or use as a biomarker. As a pseudogene, it should not be considered a classical molecular target for therapeutics. Note: If you are seeking information on the active enzyme, refer to N-alpha-acetyltransferase 20, NatB catalytic subunit (NAA20). The pseudogene (NAA20P1) itself is not a drug target and has no defined molecular or clinical functions. This entry is marked is_incorrect: true because pseudogenes like NAA20P1 do not code for a functional product and are not exploited directly in drug discovery or biology as active targets[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on NAA20 pseudogene 1 (NAA20P1).